Posted by Michael Wonder on 14 Dec 2016
Two executives charged in generic drug price-fixing federal investigation
14 December 2016 - The U.S. filed its first charges in a generic drug price-fixing probe on Wednesday.
The Justice Department charged two former Heritage Pharmaceuticals executives in Philadelphia on Wednesday. Former CEO Jeffrey Glazer and former President Jason Malek were accused of colluding with other generic pharmaceutical companies to fix prices, following a two year investigation, the report said.
The antitrust investigation includes more than a dozen companies and two dozen drugs, the publication said, citing people familiar with the matter. Several pharmaceutical companies — including Teva Pharmaceutical Industries and Mylan — have received subpoenas and are co-operating.
